SSB Acquires UK-Based CRO

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industries, has acquired the Scottish company BioOutsource Ltd. The privately owned company based in Glasgow, has been operating in the biotechnology market since 2007, and in the last twelve months earned revenue of around 9 million euros with approximately 85 employees. Details of the transaction were not disclosed.

BioOutsource provides contract testing services to monitor the safety and quality of biologic drugs and vaccines, particularly for the fast growing biosimilar industry. Reinhard Vogt, member of SSB’s Board, commented, “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”

“We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services, said Gerry MacKay, CEO of BioOutsource. “As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing.”